4.30Open4.30Pre Close0 Volume4 Open Interest12.00Strike Price0.00Turnover0.00%IV13.29%PremiumOct 18, 2024Expiry Date3.12Intrinsic Value100Multiplier-2DDays to Expiry1.18Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.73Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ginkgo Bioworks Stock Discussion
NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
Ginkgo Bioworks (NYSE: DNA) has announced a new partnership with NOVUS International to develop advanced feed additives for the animal agriculture industry. The collaboration aims to create more efficient enzymesthat can be produced cost-effectively using Ginkgo Enzyme Services. This initiative is designed to address the challenges faced by the agricultural sector, including ...
Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
Ginkgo Bioworks (NYSE: DNA) has launched two new offerings to accelerate drug development, building on its partnership with Google Cloud. The first is a protein large language model (LLM)built with Google Cloud Consulting, designed to give researchers and companies insights from Ginkgo's private data. The second is a model API, allowing direct access to biological AI models.
Th...
Lets go Bill!
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) has regained compliance with the NYSE's minimum bid price requirement. The company received confirmation on September 3, 2024, that its Class A common stock had maintained a closing bid price at or above $1.00 for the required period. This follows a 1-for-40 reverse stock split implemented on August 20, 2024, to address the previous non-compliance notification received on May 7, 2024.
Simultaneously, Ginkgo received notice tha...
No comment yet